Glenmark: steering financial deleverage through new products

Glenmark: steering financial deleverage through new products Glenmark sales, aided by strong growth in the US, increased by a healthy 16.5% but net profit grew just 3.5% and missed analysts’ estimates The Glenmark Pharmaceuticals Ltd stock has been falling steadily in the past few days. The company’s September quarter results have not been anything to write home about. Aided by strong growth in the US, sales increased by a healthy 16.5% but net profit grew just 3.5% and missed analysts’ estimates as high expenses and finance costs crimped earnings. Nevertheless, there are two factors aiding the stock. One is the Read More


ˆ Back To Top